Singapore-headquartered surgical robotics firm Biobot Surgical has announced raising S$20 million (about $15.5 million) in its latest financing round anchored by Temasek-established firm ClavystBio.
The announcement confirms DealStreetAsia’s report in April that the company raised fresh funding from new investor ClavystBio and existing cornerstone shareholder ZIG Ventures Limited.
The company said on Monday that the fresh capital will be used to expand adoption of its Mona Lisa robotic platform for prostate cancer diagnosis and treatment, strengthen its clinical evidence base, and build commercial capabilities in key overseas markets.
Biobot said its Mona Lisa platform combines robotic needle guidance with MRI-ultrasound image fusion to support targeted prostate biopsies and focal ablation procedures.
The company said it has installed more than 80 systems worldwide and supported over 30,000 patients, with deployments across hospitals in Europe and the Asia-Pacific region.
It added that more than 50 real-world clinical studies have been published on the platform.
As part of its US expansion strategy, Biobot will partner with Silicon Valley-based healthcare innovation group Fogarty Innovation to identify priority clinical segments, deepen engagement with physicians, and accelerate commercial adoption.
“The objective is not simply to place systems, but to build Mona Lisa into a precision intervention platform for prostate care,” Biobot Surgical deputy chairman and CEO Sim Kok Hwee said in a statement.
The funding adds to Biobot’s institutional backing, with its cap table comprising a mix of individual and institutional investors.
Among the individual investors are oncologist Ang Peng Tiam and Lui Pao Chuen, a distinguished defence scientist.
On the institutional side, Astrid Hill Investment joins ZIG Ventures in the round. Other corporate investors include KUPA, PTSM Holdings, and Jia Yu Capital Pte. Ltd.
Biobot’s top shareholders
Founded in 2017, BIOBOT Surgical offers robotic-assisted biopsy and treatment for prostate cancer. It says it has completed more than 23,000 procedures and has secured five key regulatory clearances to date.
Lead investor ClavystBio was established by Temasek to invest in biotechnology and medical technology startups emerging from Asia. It backs companies developing first-in-class healthcare technologies and supports their commercialisation into global markets.
